adenosine and s 1033
adenosine has been researched along with s 1033 in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Eadie, LN; Hughes, TP; Saunders, VA; White, DL | 1 |
| Ambudkar, SV; Bakhsheshian, J; Chang, KE; Gottesman, MM; Hall, MD; Shukla, S; Simpson, RM; Wei, BR | 1 |
Reviews
1 review(s) available for adenosine and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Other Studies
2 other study(ies) available for adenosine and s 1033
| Article | Year |
|---|---|
Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Biological Transport; Blotting, Western; Cyclosporins; Diketopiperazines; Dose-Response Relationship, Drug; Flow Cytometry; Heterocyclic Compounds, 4 or More Rings; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2013 |
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Topics: 3T3 Cells; Adenosine; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Cell Line, Tumor; Diketopiperazines; Endothelial Cells; Firefly Luciferin; Gefitinib; Gene Expression; HEK293 Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Luciferases, Firefly; Luminescent Agents; Luminescent Measurements; Mice; Mice, Transgenic; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Xenobiotics | 2013 |